Retatrutide (LY3437943) is an investigational triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors. It is currently in Phase 3 clinical trials (TRIUMPH program) for the treatment of obesity, obstructive sleep apnea, and metabolic dysfunction.

Is retatrutide FDA approved?

No, as of 2026, retatrutide has not yet been approved by the FDA or EMA. It is currently undergoing Phase 3 clinical trials focusing on safety and efficacy markers including weight-loss, liver fat reduction, and dysesthesia tracking.

What makes retatrutide different from tirzepatide or semaglutide?

Unlike semaglutide (a single GLP-1 agonist) and tirzepatide (a dual GIP/GLP-1 agonist), retatrutide adds a third mechanism: glucagon receptor agonism. This triple-action approach aims to significantly increase energy expenditure while reducing appetite.

Retatrutide Sleep Apnea Improvement Weight Loss Trial Data

Retatrutide, a novel triple agonist,[1] has shown substantial weight loss in clinical trials, with TRIUMPH-4 results revealing up to 28.7% body weight reduction at the 12 mg dose after 68 weeks.[2] This retatrutide sleep apnea improvement weight loss trial data suggests potential benefits for obstructive sleep apnea (OSA) patients, as significant weight loss often correlates with reductions in apnea-hypopnea index (AHI).[3] While Phase 3 OSA-specific outcomes from the TRIUMPH program's GSA1 subsets are pending until 2026,[1] early data positions retatrutide as a promising dual therapy for obesity and OSA.

Introduction to Retatrutide Sleep Apnea Improvement Weight Loss Trial Data

Retatrutide represents a breakthrough in obesity management with implications for sleep apnea treatment. Developed by Eli Lilly, it targets multiple hormones to drive weight loss,[1] a key factor in improving OSA symptoms. The retatrutide sleep apnea improvement weight loss trial data from ongoing Phase 3 studies highlight its potential to address both conditions simultaneously.

What is Retatrutide and Its Triple Agonist Mechanism?

Retatrutide (LY3437943) is an investigational drug that activates three receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon.[3] This triple action enhances insulin secretion, suppresses appetite, and boosts energy expenditure, leading to profound weight loss.

Unlike single or dual agonists like semaglutide or tirzepatide, retatrutide's broader mechanism leads to greater weight loss in trials—up to 28.7% in Phase 3 data.[2] For more on this, see the retatrutide triple agonist mechanism.

In practice, this means patients may lose more weight faster, which is crucial for OSA where every pound counts toward better breathing at night.

Why Weight Loss Matters for Obstructive Sleep Apnea (OSA)

Obesity contributes to OSA by narrowing airways through excess fat around the neck and tongue. Studies show that losing 10-15% of body weight can reduce AHI by 50% or more in many patients, sometimes allowing CPAP discontinuation.

The retatrutide sleep apnea improvement weight loss trial data emphasizes this link, as doses achieving 20-30% loss could transform OSA management.[4] Patients report less daytime fatigue and better quality of life with sustained fat reduction.

Real-world evidence from other weight loss drugs supports this: a 10% loss improves oxygen levels and sleep architecture.

Overview of the TRIUMPH Phase 3 Clinical Trial Program

The TRIUMPH program includes four registrational Phase 3 trials evaluating retatrutide against placebo in over 5,800 adults with obesity or overweight.[1] It uses a basket design, nesting OSA (GSA1) and knee osteoarthritis (GOA1) subsets within weight management studies for efficient data collection.[1]

Trials began in 2023,[1] with durations up to 104 weeks including optional extensions. TRIUMPH-4 has topline results from December 2025,[2] while OSA data from GSA1 awaits 2026 readout.[1] Key details are available on ClinicalTrials.gov (TRIUMPH-1).

This program controls statistical errors rigorously, ensuring reliable retatrutide sleep apnea improvement weight loss trial data.[1]

Retatrutide Mechanism of Action and Dosing

Retatrutide works by mimicking gut hormones to regulate metabolism and hunger. Its design aims for superior weight loss compared to existing therapies like semaglutide, which tops at ~15-20%.

The retatrutide sleep apnea improvement weight loss trial data underscores how this mechanism indirectly targets OSA by shrinking fat deposits.

Triple Agonist: GIP, GLP-1, and Glucagon Receptor Activation

GIP improves insulin sensitivity and fat metabolism, GLP-1 slows gastric emptying and curbs appetite, and glucagon increases fat burning while preserving muscle.[3] This synergy explains retatrutide's efficacy in retatrutide sleep apnea improvement weight loss trial data.

The combination targets both central (brain) and peripheral (liver, fat) pathways for sustained weight reduction. Detailed mechanisms are covered in the retatrutide triple agonist mechanism.

Compared to tirzepatide (dual GIP/GLP-1), adding glucagon boosts calorie burn by 10-20% more.

Once-Weekly Subcutaneous Administration and Tested Doses (4mg, 9mg, 12mg)

Patients self-administer retatrutide via weekly injections,[1] starting at low doses and titrating up over weeks. Tested maintenance is 4 mg, with escalation to 9 mg or 12 mg based on tolerance.[1]

Higher doses correlate with greater weight loss but may increase side effects like nausea. Titration minimizes gastrointestinal issues common to this class, improving adherence.

In trials, 12 mg yielded the best results, relevant for severe OSA cases needing maximal intervention.[2]

How Retatrutide Targets Obesity and OSA Through Weight Loss

By promoting 20-30% weight loss, retatrutide reduces neck circumference by 2-4 inches and airway fat, key OSA drivers. Phase 2 data linked 24.2% loss to metabolic and sleep gains.[3]

This positions retatrutide as a non-surgical option for comorbid obesity and OSA, potentially outperforming lifestyle changes alone. Ongoing trials quantify AHI changes directly, building on this foundation.[1]

Patient stories from similar drugs show improved sleep scores after 6-12 months.

TRIUMPH Program: Clinical Trial Design and Status

TRIUMPH is a randomized, double-blind, placebo-controlled program emphasizing real-world relevance with diet and exercise counseling.[1] It controls for Type I error (α=0.05) across endpoints, ensuring robust retatrutide sleep apnea improvement weight loss trial data.[1]

Over 5,800 diverse participants (BMI ≥30 or ≥27 with comorbidities) reflect typical OSA patients.[1]

Key Trials: TRIUMPH-1, TRIUMPH-2, TRIUMPH-3, and TRIUMPH-4

TRIUMPH-1: Obesity/overweight without diabetes, including GSA1 OSA and GOA1 OA subsets (up to 104 weeks).[1]
TRIUMPH-2: Similar basket for type 2 diabetes patients with OSA/OA nests.[1]
TRIUMPH-3: Weight management in cardiovascular disease comorbidities.[1]
TRIUMPH-4: Knee OA-focused, completed with positive topline results December 2025.[2]

Basket design allows subset analyses without separate trials. See Eli Lilly TRIUMPH Overview.

Seven additional Phase 3 trials in obesity/T2D wrap up in 2026.[1]

Basket Design with OSA (GSA1) and OA (GOA1) Subsets

Subsets evaluate condition-specific endpoints within weight loss trials. OSA patients must have moderate-to-severe disease (AHI ≥15) confirmed by polysomnography at baseline.[1]

This efficient approach speeds development for multiple indications like obesity, OSA, and OA. The GOA1 subset saw knee osteoarthritis pain relief in TRIUMPH-4, mirroring potential for OSA.

Independent statistical testing preserves power.

Enrollment, Duration, and Statistical Controls (>5,800 Participants)

Over 5,800 participants enrolled since 2023 across global sites.[1] Core trials last 80-104 weeks, assessing long-term durability.

Alpha split ensures no inflation of false positives. Interim safety reviews protect participants.

This scale provides the strongest retatrutide sleep apnea improvement weight loss trial data yet.

Primary and Secondary Endpoints in Retatrutide Trials

Endpoints measure weight, sleep metrics, and quality of life per FDA guidance. They capture both direct (AHI) and indirect (weight) OSA benefits.[1]

Hierarchical testing prioritizes weight loss, then disease-specific outcomes.

Weight Management: Percent Body Weight Change at Week 80/104

Primary: Percent change from baseline body weight. Secondaries: absolute kg loss, ≥5%/10%/15% responders.[1]

TRIUMPH-4 exceeded targets, driving the retatrutide sleep apnea improvement weight loss trial data narrative.[2]

Comparable to semaglutide's SELECT trial but superior in magnitude.

OSA Endpoints: AHI Reduction, ≥50% Improvement, and Remission Criteria

Primary (GSA1): Change in AHI (events/hour) at Week 80.[1] Key secondaries: % with ≥50% AHI reduction; remission (% with AHI <5 or AHI 5-14 + ESS ≤10).[1]

Polysomnography confirms changes. These align with OSA drug approvals like tirzepatide analogs.

Additional Measures: FOSQ-10, ESS, Neck Circumference, and Oxygen Saturation

FOSQ-10: Functional Outcomes of Sleep Questionnaire—assesses daily impacts.[1]
ESS: Epworth Sleepiness Scale—daytime drowsiness.[1]
Neck circumference: Simple proxy for fat reduction.
Oxygen saturation: Nighttime hypoxia levels.

Win-ratio analyses combine these for holistic views.

Efficacy Results: Weight Loss Data from Retatrutide Trials

Weight loss is retatrutide's cornerstone, with dose-dependent effects surpassing GLP-1s. TRIUMPH-4 data sets benchmarks for OSA expectations.[2]

Phase 2 showed no plateau at 48 weeks, promising durability.[3]

TRIUMPH-4 Results: 28.7% Weight Loss at 12mg Dose (68 Weeks)

In knee OA patients (84% BMI ≥35 kg/m²), 12 mg yielded 28.7% loss (~71 lbs average).[2] Both 9 mg and 12 mg met all primary/secondary endpoints.

See full TRIUMPH-4 28.7% weight loss results. Superior to semaglutide (15-20%) and tirzepatide (21-22%).

This level supports major OSA remission.

Phase 2 Data: Up to 24.2% Loss and Links to OSA Improvement

Phase 2 obesity trial (338 adults): 24.2% at 12 mg (48 weeks) vs. 2.1% placebo.[3] T2D trial: 16.9% loss.[3]

Linked to metabolic gains; 15-20% loss halves AHI in literature. Builds excitement for Phase 3 retatrutide sleep apnea improvement weight loss trial data.

Comparisons Across Doses and Populations (BMI ≥35 kg/m²)

Dose	% Weight Loss (TRIUMPH-4, 68w)	Population Notes
4 mg	Maintenance (~15-20%, est.)	Lower intensity, sustained loss
9 mg	Met endpoints (~25%, est.)	Balanced efficacy/safety
12 mg	28.7%[2]	Highest; BMI ≥35 dominant

Consistent in high-BMI groups relevant to OSA. Vs. placebo: 3-4x greater loss.

Sleep Apnea Improvement: Retatrutide Trial Data and Expectations

Weight loss drives OSA gains, but direct Phase 3 data is emerging. Expectations: 20%+ loss yields 50%+ AHI drop.

Variability noted; not all remit fully.

Expected AHI Reductions Driven by 15-20%+ Weight Loss

Literature: 10% loss reduces AHI ~26%; 20% ~50%. Retatrutide's 25%+ exceeds, potentially remitting 30-50% of cases.

Neck fat loss (2-5 cm) correlates strongly. Retatrutide sleep apnea improvement weight loss trial data will confirm.

Hypothetical: A 300 lb patient loses 75 lbs, halving AHI from 40 to 20.

Phase 3 OSA Data Pending: GSA1 Subset Outcomes at Week 80

GSA1 primary: AHI reduction via PSG.[1] No topline yet; full results 2026.

Basket isolates OSA signals amid weight loss. Promising proxy from TRIUMPH-4.[2]

Patient-Reported Outcomes and CPAP Reduction Potential

FOSQ-10/ESS track symptoms; expect 20-30% improvements.[1] Weight loss may allow CPAP weaning in 40-60% responders.

Holistic gains: energy, mood. See NEJM Phase 2 Insights.

Safety Data and Side Effects in Retatrutide Trials

Safety mirrors GLP-1 class: mostly mild GI events resolving with time. The retatrutide sleep apnea improvement weight loss trial data includes monitoring for OSA-specific risks like desaturation.

No new signals in topline; cardiac safe.[2]

Adverse Event Discontinuations: 8.8-12.1% vs. 4.8% Placebo

TRIUMPH-4: 12.1% (12 mg), 8.8% (9 mg) vs. 4.8% placebo.[2] Primarily GI-driven.

Manageable with slow titration. For strategies, see managing retatrutide side effects at 12mg.

Lower than early GLP-1 trials.

Known Safety Profile from TRIUMPH-4 and Phase 2

GI: Nausea (40-50%, peak week 4), vomiting/diarrhea (20-30%, transient).[2]
Other: Mild heart rate +5 bpm; injection site reactions <5%.
Serious: No deaths, severe hypo, or pancreatitis in Phase 2/3 topline.[3]

Muscle preservation better than diet alone.

Ongoing Monitoring in OSA and Weight Loss Cohorts

Basket trials track oxygen, vigilance. Full profiles post-2026; compares favorably to semaglutide OSA trials.

Legal Status, FDA Approval, and Future Timeline

Retatrutide remains investigational amid strong data.[1] Path mirrors tirzepatide's rapid approval post-Phase 3.

Current Investigational Status: Not FDA Approved

Available only in trials. No commercial access; off-label unavailable.

TRIUMPH Results Expected in 2026 and Additional Phase 3 Trials

Topline TRIUMPH-1/2/3: H1 2026. Seven more obesity/T2D trials complete then.[1] See TRIUMPH trials completion dates and NDA impact.

Peer-reviewed pubs follow.

Regulatory Path for Obesity, OSA, and Knee OA Indications

NDA possible Q4 2026: obesity first (weight endpoint), then OSA/OA labels. retatrutide NDA submission timeline eyes March 2026 filing.

Global (EMA) parallel; priority review likely.

The retatrutide sleep apnea improvement weight loss trial data will anchor filings.

Conclusion: The Promise of Retatrutide for OSA and Weight Loss

Retatrutide sleep apnea improvement weight loss trial data highlights its potential to transform care for millions with obesity-driven OSA.

Key Takeaways from Available Trial Data

Up to 28.7% weight loss in Phase 3 TRIUMPH-4.[2]
Pending but expected OSA AHI reductions via GSA1.[1]
Favorable safety; dose-dependent benefits.[2]

Superior to current options.